FOXP3 and head and neck squamous cell carcinoma: Other molecules, such as TIGIT and FOXP3, have been investigated as regulatory key points of the TME and, therefore, as potential targets of new immunotherapeutic drugs [52,53], and so-called tertiary lymphoid structures, as shown to be important in prediction of the outcome in HNSCC [54].